A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period
Public ClinicalTrials.gov record NCT06524375. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase II, Open-label, Prospective Single-arm, Multi-center Clinical Trial to Evaluate if Adding Venetoclax to Patients on Covalent BTKi For 1L CLL Can Achieve Deep Durable Remissions (by UMRD 10^-4) to Allow Off-treatment Period
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The main purpose of the study is to evaluate if adding venetoclax to participants receiving cBTKi for the 1L CLL can achieve deep durable remissions of undetectable measurable residual disease \[uMRD \< or 10\^-4 in peripheral blood (PB)\] by end of combination treatment (EOCT) to allow off-treatment period. The acronym BRAVE stands for Btki Responders to Achieve deep remission (or off-treatment periods) with VEnetoclax.
Study identification
- NCT ID
- NCT06524375
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 118 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 9, 2024 (Actual)
- Primary completion
- Oct 31, 2026 (Estimated)
- Completion
- Jan 31, 2030 (Estimated)
- Last update posted
- Sep 28, 2026
2024 – 2030
United States locations
- U.S. sites
- 20
- U.S. states
- 15
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Highlands Oncology Group | Springdale | Arkansas | 72762 | — |
| Rocky Mountain Cancer Centers (Aurora) - USOR | Aurora | Colorado | 80012-5405 | — |
| Cancer Specialists of North Florida | Jacksonville | Florida | 32256-6932 | — |
| Fort Wayne Medical Oncology and Hematology, Inc | Fort Wayne | Indiana | 46804 | — |
| Mission Blood and Cancer - MercyOne Cancer Center | Des Moines | Iowa | 50314-3030 | — |
| American Oncology Partners of Maryland, PA | Bethesda | Maryland | 20817-1915 | — |
| Dana-Farber Cancer Institute - Hematologic Oncology Treatment Center | Boston | Massachusetts | 02215-5418 | — |
| Nebraska Cancer Specialists St Francis - Grand Island | Grand Island | Nebraska | 68803 | — |
| Nebraska Cancer Specialists | Omaha | Nebraska | 68130-2042 | — |
| Astera Cancer Care East Brunswick | East Brunswick | New Jersey | 08816-4096 | — |
| San Juan Oncology Associates, PC | Farmington | New Mexico | 87401 | — |
| Oncology Hematology Care Inc - Cincinnati - USOR | Cincinnati | Ohio | 45236-2725 | — |
| Ohio State University | Columbus | Ohio | 43210 | — |
| Willamette Valley Cancer Institute and Research Center | Eugene | Oregon | 97401-6043 | — |
| Asante Rogue Regional Medical Center | Medford | Oregon | 97504-8332 | — |
| Tennessee Oncology, PLLC - Chattanooga | Chattanooga | Tennessee | 37404 | — |
| Tennessee Oncology - Midtown | Nashville | Tennessee | 37203 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Texas Oncology- Northeast Texas | Tyler | Texas | 75702 | — |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06524375, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 28, 2026 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06524375 live on ClinicalTrials.gov.